Although a large number of new agents targeting the EGFR pathways are being tested and have shown certain efficacy through greater survival in clinical and pre-clinical models, it remains unclear as to how combination EGFR therapy with chemotherapy will impact breast cancer patients. The gene discussed is EGFR; the disease is breast carcinoma.